Avisi Technologies Secures $10.7M Funding to Propel Glaucoma Device Innovation

Avisi Technologies Secures $10.7 Million for Glaucoma Device Development

Avisi Technologies, an innovative player in the ophthalmic medical device field, has successfully closed a funding round totaling $10.7 million. This Series A financing, primarily led by MedVenture Partners, includes contributions from both new and existing investors such as Sherpa Healthcare Partners, SNBL-Gemseki, and SBI US Gateway Fund. The fresh capital is intended to advance the development of their groundbreaking glaucoma treatment device, VisiPlate®, as well as facilitate the pivotal SAPPHIRE clinical trial.

The VisiPlate® Device

The VisiPlate® device is an aqueous shunt, characterized by a unique design that incorporates an ultra-thin metamaterial, significantly thinner than a human hair. Unlike conventional glaucoma treatments, VisiPlate® features multiple redundant microchannels that ensure sustained aqueous flow, decreasing the chance of blockage—a common issue in existing treatment solutions.

Clinical Trial – SAPPHIRE

The SAPPHIRE trial is designed to rigorously assess the safety and efficacy of the VisiPlate® in reducing intraocular pressure (IOP). The device has already received FDA Investigational Device Exemption (IDE) approval in 2025, a significant milestone that allows Avisi to proceed with the trial. Justin Fukuyama, a Partner at MedVenture Partners and now a member of Avisi’s Board of Directors, stressed the critical need for advancements in glaucoma treatment, stating that the device addresses a significant gap in patient care.

Addressing Unmet Needs

Darren Cai, Managing Partner at Sherpa Healthcare Partners, expressed optimism regarding the VisiPlate®, highlighting its potential to redefine glaucoma treatment. Existing options often suffer from issues of patient compliance and longevity, stating, "avis understands the unmet needs of glaucoma patients through innovative design." With the new funding, Avisi plans to continue addressing these long-standing issues in the field.

The Impact of Glaucoma

Glaucoma is recognized as the primary cause of irreversible blindness globally, affecting more than 133 million people. Increased intraocular pressure can severely damage the optic nerve, leading to permanent vision loss. Standard treatments include medications, laser therapies, and surgical interventions, but they often fail due to complications arising from patient adherence and device occlusions over time.

Current methods for managing glaucoma are limited, and there remains a persistent need for effective, safe interventions that improve overall patient outcomes and enhance quality of life. The VisiPlate® aims to fulfill this gap, offering a promising long-term solution.

Company Vision and Future

Rui Jing Jiang, Founder and CEO of Avisi Technologies, is optimistic about the future. He stated, "Our successful capital raise showcases the compelling data and expertise behind VisiPlate®. We aim to collaborate with our esteemed investors and leading clinicians to ensure a successful pivotal trial and bring this vision-saving technology to those who need it most."

In conclusion, Avisi Technologies' recent funding marks a significant step forward not only for the company but also for patients battling glaucoma. With VisiPlate®, they aspire to transform treatment options and ultimately preserve vision for millions around the world.

For anyone interested in learning more about the SAPPHIRE clinical trial or the technology behind VisiPlate®, further information is available on Avisi Technologies’ official website.